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Little is known about the factors that enable the mobilisation of human mesenchymal stem cells (MSC) from the bone marrow into
the blood stream and their recruitment to and retention in the tumour. We found specific migration of MSC towards growth factors
present in pancreatic tumours, such as PDGF, EGF, VEGF and specific inhibitors Glivec, Erbitux and Avastin interfered with migration.
Within a few hours, MSC migrated into spheroids consisting of pancreatic cancer cells, fibroblasts and endothelial cells as measured
by time-lapse microscopy. Supernatant from subconfluent MSC increased sprouting of HUVEC due to VEGF production by MSC
itself as demonstrated by RT-PCR and ELISA. Only few MSCs were differentiated into endothelial cells in vitro, whereas in vivo
differentiation was not observed. Lentiviral GFP-marked MSCs, injected in nude mice xenografted with orthotopic pancreatic
tumours, preferentially migrated into the tumours as observed by FACS analysis of green fluorescent cells. By immunofluorescence
and intravital microscopic studies, we found the interaction of MSC with the endothelium of blood vessels. Mesenchymal stem cells
supported tumour angiogenesis in vivo, that is CD31
þ vessel density was increased after the transfer of MSC compared with siVEGF-
MSC. Our data demonstrate the migration of MSC toward tumour vessels and suggest a supportive role in angiogenesis.
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The plastic adherent cells from the bone marrow (BM) referred to
as mesenchymal stem cells (MSC) are capable of self-renewing and
have the potential to differentiate into mesenchymal and non-
mesenchymal tissues (Prockop, 1997). Mesenchymal stem cells
contribute to tissue regeneration by differentiation into bone,
cartilage, muscle, ligament, tendon, adipose tissue, and stroma
(Pittenger et al, 1999). The ability of MSC to migrate to the areas of
injury and to tumours has encouraged investigation of MSC as
therapeutic tools. For example, systemically administered MSCs
have been shown to improve recovery in animal models of stroke
and myocardial infarction (Mahmood et al, 2003; Fukuda and
Fujita, 2005). Mesenchymal stem cells have also been used for
targeted delivery of therapeutic gene products to the tumour
microenvironment in animal models (Studeny et al, 2002, 2004;
Nakamizo et al, 2005). This shared tropism of MSC for sites of
injured tissue and for tumours is believed to result from
similarities in the inflammatory milieu produced by healing
wounds and tumours, evoking the notion that ‘tumours are
wounds that never heal’ (Dvorak, 1986). Furthermore, a role of
MSC in neoangiogenesis is discussed, as the administration of MSC
stimulated revascularisation of ischaemic tissues (Chen et al, 2003;
Nagaya et al, 2004). A correlation between angiogenesis in
melanoma and MSC has recently been demonstrated (Sun et al,
2005), and MSC have been found to transmigrate over the
endothelial barrier (Schmidt et al, 2006b). In all cases, MSCs had
to cover a distance to reach the target area. Therefore, the common
hypothesis is that MSC possess a migratory activity. The most
prominent chemotactic factors identified thus far for MSC include
SDF-1, basic fibroblast growth factor and vascular endothelial
growth factor (VEGF) (Schmidt et al, 2006a). The concept of
chemokines as possible chemoattractants for MSC may be of
importance for pancreatic cancer, as this tumour entity contains
poorly vascularised regions characterised by severe hypoxia
resulting in the expression of growth factors (Bos et al, 2005;
Patiar and Harris, 2006).
It has been suggested that the MSC-mediated effects can be
attributed, at least in part, to the biologically active factors
secreted by MSC itself at their target sites. Even more, a direct
contribution of MSC to the blood vessel formation is suggested, as
differentiation of MSC into endothelial cells has been demonstrated
(Oswald et al, 2004; Silva et al, 2005; Song et al, 2007), although this
concept remains controversial. Here, we test the hypothesis that
hypoxia-induced growth factor expression in pancreatic cancer
promotes tumour angiogenesis by mediating MSC recruitment.
We assessed this hypothesis by in vitro studies and in an
orthotopic mouse model of pancreatic carcinoma. We demonstrate
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sthe migration of MSC towards growing normal and tumour cells,
as well as to platelet-derived growth factor (PDGF), epidermal
growth factor (EGF), and vascular epidermal growth factor
(VEGF). Inhibitors of PDGFR (Glivec), EGFR (Erbitux) and
blocking antibody to VEGF (Avastin) interfered with MSC
migration demonstrating the specific growth factor-mediated
effect. Within a few hours, MSC migrated into pancreatic
tumour cell spheroids as measured by time-lapse microscopy.
Mesenchymal stem cells themselves secreted VEGF, and the
transfer of supernatant from cultured MSC induced sprouting of
endothelial cells. Differentiation of MSC to endothelial cells was
observed in only few cells in vitro but not in vivo. However, MSC
inoculated in nude mice xenografted with orthotopic pancreatic
tumours were found to home into the tumours and to incorporate
in tumour blood vessels. Our conclusion is that MSC contribute to
the tumour blood vessel formation by homing to fast growing
tumours and the incorporation into blood vessels as atypical
VEGF-secreting endothelial cells.
MATERIALS AND METHODS
Isolation and culture of human BM-derived MSC
Mesenchymal stem cells were isolated from human BM of healthy
donors, selected by plastic adherence, and were cultivated as
described in our recent publication (Kallifatidis et al, 2008).
Primary and established human cell lines
Established human standard cancer cell lines of pancreas (Capan-1,
MIA-Pa-Ca2, Colo-357, and BxPC-3), immortalised human
kidney cells (HEK 293T), and human primary fibroblasts from
the skin (kind gift from J Knebel and P Angel) were cultured in
DMEM supplemented with 10% FCS. Human umbilical vein
endothelial cells (HUVEC; PromoCell, Heidelberg, Germany) were
cultured in endothelial cell growth medium (ECGM; PromoCell).
Migration of MSC to chemoattractants measured by
transwell chamber migration assay
A ChemoTx
s System (Neuro Probe Inc., Gaithersburg, MD, USA)
with 96 wells or Transwell
s permeable supports (Corning
Incorporated, Life Sciences, Acton, MA, USA) and a polycarbonate
membrane pore size of 12mm was used. The bottom chamber
contained PDGF (R&D Systems, Wiesbaden-Nordenstadt,
Germany), EGF (R&D Systems), or VEGF (BioSource, Nivelles,
Belgium) in medium with 2% FCS or cell culture supernatant of
tumour cells grown in medium supplemented with 2% FCS for 2
days. Growth factors were used with or without specific inhibitors:
Avastin for the inhibition of VEGF (25mgml
 1; Roche, Welwyn
Garden City, Hertfordshire, UK), Glivec for the inhibition of PDGF
receptors (3mM; Novartis, Horsham, West Sussex, UK), and
Erbitux for the inhibition of EGF receptors (3mM; Merck,
Darmstadt, Germany). The migration of MSC was analysed as
described in our recent publication (Kallifatidis et al, 2008).
Generation of tumour cell spheroids
Spheroids were generated as described (Korff et al,2 0 0 4 ) .C o n f l u e n t
monolayers of MIA-PaCa-2 cells, primary fibroblasts, and HUVEC
were trypsinised. A total of 500 MIA-PaCa-2 cells, 250 fibroblasts,
and 250 HUVECs per spheroid were mixed in corresponding culture
medium containing 0.25% (w/v) methylcellulose (Sigma, Steinheim,
Germany) and seeded in nonadherent round bottom 96-well plates
(Greiner, Frickenhausen, Germany). Under these conditions, all
suspended cells contribute to the formation of a single spheroid per
well of defined size and cell number. Spheroids were cultured for at
least 24h and used for the corresponding assay.
Migration of MSC to tumour cell spheroids
Mesenchymal stem cells were labelled with CellTracker Red
according to the instructions of the manufacturer (Molecular
Probes, Eugene, OA, USA). A total of 1 10
4 MSCs (in a volume of
225ml) were seeded in one edge of a fibronectin-coated well of a
24-well plate by canting the plate in an angle of 301. After 24h,
MSC culture medium was removed, and cells were covered with
225ml of methylcellulose/collagen solution (40% methylcellulose
stock solution, 10% FCS, and 50% collagen solution prepared from
rat tail). Correspondingly, spheroids were labelled with Cell
Tracker Green (Molecular Probes), and 48 spheroids were seeded
opposite to the MSC in the same well. Invasion of MSC in
spheroids was documented by time-lapse microscopy and a
camera with a red filter and green filter. The camera was focused
to the green fluorescent spheroids and cells were observed over
12h on an Olympus IX70 microscope equipped with an incubation
housing around the microscope. Time-lapse imaging series were
acquired using the software analySiS from Soft Imaging System
with a ColorView-12 digital colour camera. Images were made
every 5min, for each position one with bright field and one with
fluorescence illumination in red and/or green with a motorised
Ludl X-Y microscope stage.
In vitro angiogenesis assay
Spheroids containing 750–1000 HUVECs were generated over-
night, after which they were embedded in collagen gel as described
previously (Korff et al, 2001). Supernantant of MSC or recombi-
nant VEGF (BioSource) were transferred to the spheroids. After
24h, in vitro angiogenesis was digitally quantified by measuring
the length of the sprouts that had grown out of each spheroid
(at  10 magnification) using the digital imaging software cell
B 2.3
(Olympus, Hamburg, Germany) analysing at least eight spheroids
per experimental group and experiment.
Detection of VEGF and a-smooth muscle actin in MSC by
RT-PCR
Mesenchymal stem cells were seeded in a six-well plate at a
concentration of 1 10
5 cells per well and incubated overnight
under normoxic conditions (371C, 5% CO2) followed by 16h
incubation in a hypoxia chamber (N2: 89.25%, CO2: 10%, and O2:
0.75%). Cells were scraped in 300ml per well prewarmed Magna
Pure LC Lysis buffer (mRNA isolation kit I for cells; Roche Applied
Science, RAS, Mannheim, Germany) supplemented with
0.01gml
 1 DTT from the tissue culture plates and frozen at
 801C. mRNA/cDNA preparation and real-time quantitative PCR
were performed with equipment and reagents from Roche as
described previously (Erkan et al, 2007). In brief, mRNA was
extracted by automated isolation, and cDNA was prepared using
the First Strand cDNA synthesis kit for RT-PCR (ABgene
Advanced Biotechnologie, Epsom, UK). QRT-PCR was performed
using LightCyclert primer sets obtained from Search-LC
(Heidelberg, Germany). Results are expressed as the number of
VEGF or a-SMA transcripts per 10000 CPB transcripts (cyclophilin
B, a housekeeping gene).
Lentiviral transduction of MSC
Vectors used in our study are the self-inactivating (SIN) vectors of
the second generation, which loose the activity of the promoter
located in the 50-LTR upon replication and integration into the
genome of the host cells. The construction of the pLL3.7puroeGFP
vector plasmid, VEGF siRNA, and lentiviral transduction of MSC is
described in our recent manuscript (Kallifatidis et al, 2008). In
detail, the VEGF siRNA sequence was designed against the human
VEGF mRNA (accession no. AF022375), the target sequence
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sstarting at position 465 after the start codon. Depicted
is the resulting VEGF siRNA sequence with polyA tail, siRNA
stem, loop and siRNA stem: 50-tcgagaaaaaagatccgcagacgtg
taaatgtctcttgaacatttacacgtctgcggatca-30. The construct was verified
by sequencing.
Detection of VEGF in cell culture supernatant of MSC
A volume of 5 10
4/ml lentiviral transduced or non-transduced
MSC were seeded in 12-well plates. Hypoxia was induced as
described above, and 16h later, cells were quickly removed from
hypoxic conditions by putting them on ice. The VEGF content was
estimated in supernatant and cell lysates following the instructions
of the Quantikine
s ELISA for human VEGF (R&D Systems,
Wiesbaden-Nordenstadt, Germany). Cells treated with 25mgml
 1
Avastin added at the time of hypoxia induction served as negative
control. Vascular endothelial growth factor expression was
evaluated in an ELISA plate reader at 450nm with a correction
at 570nm. Results were normalised to picogram VEGF per hour
treatment per 10
4 cells.
In vitro differentiation of MSC in endothelial cells
Mesenchymal stem cells (1 10
4/cm
2) were seeded in a six-well
plate, and for differentiation, 50ngml
 1 VEGF (Biosource,
Nivelles, Belgium) was added to standard culture medium or to
ECGM used for HUVEC culture. Differentiation to endothelial cells
was analysed by using the Chemicon (Temecula, CA, USA) blood
vessel staining kit following supplier’s instructions. Shortly, the
cells were incubated with rabbit anti-vWF polyclonal antibody
(1:200, Chemicon) or mouse anti-CD31 monoclonal antibody
(1:200, Chemicon) and detected with biotinylated goat anti-rabbit
or goat anti-mouse antibody and Streptavidin-HRP (Chemicon).
DAB/haematoxylin staining was performed by a standard protocol.
Cells were analysed with a Leica DMRB microscope (Leica
Microsystems GmbH, Wetzlar, Germany) with Kappa CF20/4 DX
Camera (Kappa Opto-Electronics GmbH, Gleichen, Germany).
Detection of microvessel density in xenografts
To examine the effects of MSC injection on the microvessel density
in xenografts, aceton-fixed frozen sections (5mm) were stained
with rat anti-mouse CD31 mAb (PharMingen, San Diego, CA,
USA) as described previously (30). Random areas of tumours were
then examined under higher magnification ( 250) and CD31
þ
structures were counted. Any distinct area of positive staining for
CD31 was counted as a single vessel. Results were expressed as the
mean number of vessels±s.e. per mm
2. A total of eight high-power
fields was examined and counted from four tumours of each of the
treatment groups.
Orthotopic pancreatic cancer xenograft model in athymic
nude mice
NMRI (nu/nu) male mice (6-to-10-weeks old) were used for
subcutaneous and orthotopic tumour implantations of the
human pancreatic cancer cell line MIA-PaCa-2 as described
previously (Buchler et al, 2007). The experimental protocol was
approved by the Chancellor’s Animal Research Committee of
the University of Heidelberg (Heidelberg, Germany) in accordance
with National Guidelines for Animal Care and the Use of
Laboratory Animals.
Detection of GFP-MSC in blood vessels of pancreatic
cancer xenografts
Cryosections were fixed in 4% PFA for 15min and permeabilised
in 0.2% Triton X-100 for 15min. The sections were incubated with
mouse anti-eGFP antibody 1:200 (JL8, BD Clontech, Heidelberg,
Germany) in PBS/5% goat serum and detected with goat
anti-mouse FITC-conjugated antibody (Invitrogen, Karlsruhe,
Germany) diluted 1:200 in PBS/5% goat serum. For secondary
staining, sections were incubated with rabbit anti-vWF antibody
1:200 (Chemicon) in PBS/5% goat serum and detected with
biotinylated goat anti-rabbit Ab 1:200 (KPL, Gaithersburg, MD,
USA) and Texas Red Avidin 1:200 (Vector Laboratories,
Peterborough, UK).
Intravital microscopy of GFP-MSC recruitment in mice
Anaesthesia, general preparation, surgical preparation of the
cremaster muscle and xenograft, intravital microscopy, and data
analysis were performed as previously described (Sperandio et al,
2001, 2006). Briefly, after anaesthesia, the trachea was intubated,
and the left carotid artery was cannulated with PE 10 tubing (ID:
0.28mm, OD: 0.61mm; Becton Dickinson) for the administration
of MSC and anaesthetics throughout the intravital microscopic
experiment. For prevention of ischaemic events, the number of
injected cells was restricted to 1 10
5 MSC/0.2ml normal saline
per application up to a total number of 4 10
5 MSC during 1h.
Intravital microscopy was conducted on an upright microscope
(Leitz, Wetzlar, Germany) with a saline immersion objective (SW
40/0.75 numerical aperture) and epifluorescence illumination
(60/s; Strobex 236, Chadwick Helmuth, Mountain View, CA,
USA; and filter block Zeiss 9). After recording, the resulting video
was digitalised to MPEG format using Thyphoon DVD maker and
TVR software (ANUBIS Electronic Ltd., Kowloon, Hong Kong).
Statistical analysis
Data are presented as the mean±s.e. For in vitro experiments,
Student’s t-test was used to evaluate the differences between
groups. For in vivo experiments, Mann–Whitney U-test was used
to evaluate the differences between groups. In both calculations,
Po0.05 was considered statistically significant.
RESULTS
Isolation and expansion of human MSC
Bone marrow aspirates were obtained from normal human donors,
isolated, and expanded according to our recent publication
(Kallifatidis et al, 2008). Cells had a typical spindle shape,
consistent with the morphology reported by others (Pittenger
and Marshak, 2001). Although MSC do not have a specific antigen
profile, we verified for each culture that isolated cells were negative
for typical haematopoietic antigens CD45, CD34, and CD38 and
were positive for CD44 and CD105 (data not shown). The doubling
time of our cultures varied between 30 and 40h, and cells could be
expanded to 8–12 passages before reaching senescence. Thus,
based on available criteria, the cells used in our experiments had
the properties of human MSC as described.
Specific migration of MSC to PDGF, EGF, and VEGF
Factors released by cancer cells may be potential mediators of MSC
migration. To test this hypothesis, we performed in vitro migration
assays using Transwell plates to evaluate the tropism of human
MSC for cancer cells. We first investigated if human established
pancreatic cancer cell lines were capable of stimulating the
migration of MSC. Normal cells, such as T293, primary fibroblasts,
and endothelial cells, were also investigated. Mesenchymal stem
cells were placed in the upper wells, and conditioned medium from
cells grown in medium with 2% FCS was placed in the lower wells.
Cell-free medium with 20 or 2% FCS was used as positive and
negative controls, respectively. A semiporous membrane (12mm
VEGF expression by MSC in angiogenesis
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spores) separated the wells. Migration was quantified by directly
visualising and counting migrated cells under the microscope after
cell staining. Exposure to cell-free medium with 20% FCS and to all
cell-conditioned media resulted in significant migration of MSC,
when compared with cell-free medium with 2% FCS (Figure 1A).
The observed differences in migration were not due to the increase
in MSC proliferation because the total number of MSC (migrating
plus nonmigrating) was the same for each condition. As 20% FCS
and conditioned medium from growing cells stimulated significant
MSC migration, it is plausible that growth factors may be
chemoattractants for MSC. Therefore, to analyse the role of growth
factors in MSC migration, PDGF, EGF, or VEGF was added to the
lower wells. Maximal MSC migration occurred with exposure to
PDGF. Intermediate levels of migration were observed after
exposure to EGF followed by VEGF, which had a significant effect
compared with control medium with 2% FCS (Figure 1B). To
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Figure 1 Migration of MSC to growing tumour and normal cells, VEGF, PDGF, and EGF. (A) Established cell lines from pancreatic cancer (Capan-1,
Colo357, BxPc-3, and MIA-PaCa-2), kidney (T293), and primary cell lines from fibroblasts and endothelial cells were cultured in medium containing 2% FCS
for 48h. Supernatant was transferred to the lower well and migration of MSC placed to the upper well was measured in a ChemoTx system as described in
Materials and methods. Pos Co, cell-free medium with 20% FCS; Neg Co, cell-free medium with 2% FCS. (B) Dose-dependent migration of MSC towards
medium containing 2% FCS alone (CO) or to VEGF, PDGF, and EGF in 2% FCS and in concentrations indicated. (C) Migration of MSC to growth factors
alone (GF alone) or to growth factors in the presence of the inhibitor of PDGF receptor (Glivec, 3mM), or blocking antibodies to EGF receptor (Erbitux,
3mM), or VEGF (Avastin, 25mg/ml). (D) Induction of HIF-1a and secretion of VEGF by pancreatic cancer cells following hypoxia. For the induction of
hypoxia, the pancreatic cancer cell line BxPc-3 was treated with CoCl2 (100mM). Two to 16h later, protein expression of HIF-1a was examined by western
blot analysis. b-Actin served as a control for equal conditions. For the evaluation of VEGF secretion, a six-well plate with growing BxPc-3 cells was placed in a
modular incubator chamber and hypoxia was induced by floating with a preanalysed air mixture (89.25% N2, 10% CO2, 0.75% O2)a t3 7 1C for 16h.
Immediately thereafter, VEGF secretion into the supernatant was analysed by the ELISA assay, as described in Materials and methods. Results presented are
from three independent experiments and s.d. are shown.
VEGF expression by MSC in angiogenesis
BM Beckermann et al
625
British Journal of Cancer (2008) 99(4), 622–631 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sdocument that the increase in migration of MSC was specifically
due to the presence of growth factors, inhibitors of PDGFR
(Glivec), EGFR (Erbitux), and VEGF (Avastin) were added together
with growth factors. These blocking substances prevented the
activity of the respective growth factors (Figure 1C), suggesting
specific migration of MSC to growth factors. As migration of MSC
towards VEGF is the link to tumour angiogenesis, we examined
VEGF expression by pancreatic cancer cells. Because VEGF is
under the control of the transcription factor HIF-1a, which is
induced by tumour hypoxia, we performed western blot
experiments using BxPc-3 cells grown under normoxic and
hypoxic conditions. Strong induction of HIF-1a was observed as
early as 2h after hypoxia, which lasted for 16h and dropped
down to basal levels after 24h (Figure 1D). In parallel, BxPc-3
cells secreted VEGF into the supernatant, which could be
completely blocked by adding Avastin to the cell culture medium
as measured by an ELISA assay. Thus, it appears that
enhanced levels of VEGF and other growth factors secreted by
pancreatic cancer cells under hypoxic conditions lead to the
migration of MSC.
MSC are attracted by reconstructs of tumour blood vessels
To examine, whether MSC may be attracted to tumour blood vessel
reconstructs, we created tumour cell spheroids. These consisted of
MIA-PaCa-2 pancreatic cancer cells, primary fibroblasts, and
HUVECs. Pancreatic cancer cells and fibroblasts are known to
overexpress many growth factors (Korc, 2007), including VEGF
(Sipos et al, 2002). This, in turn, may lead to the paracrine
stimulation of PDGF expression in HUVECs as recently described
(Reinmuth et al, 2007). Therefore, tumour cell spheroids may be
strong chemoattractants for MSC. To prove this hypothesis, green
fluorescent spheroids and red fluorescent MSC were seeded
opposite in wells of a 24-well plate and separated by a
methylcellulose/collagen solution (Figure 2A). The invasion of
MSC into spheroids was documented by time-lapse microscopy
over 12h focused on the green fluorescent spheroids. Within 1h,
red MSC came into the focus, indicating that MSC migrate to the
spheroids (Figure 2B). Migration was completed within 5h. These
results suggest the migration of MSC to pancreatic tumour
spheroids.
MSC induce sprouting but do not differentiate into
endothelial cells in vitro
To investigate the effects of paracrine factors secreted by MSC on
angiogenesis, we measured VEGF expression in MSC cultured
under normoxic and hypoxic conditions. The secretion of VEGF in
cell culture supernatant was analysed by the ELISA assay and the
expression of RNA by RT-PCR. By this way, we found that MSC
express a basal level of VEGF protein and RNA, which could be
enhanced by hypoxia (Figure 3A and B). Total blocking of basal
and induced VEGF expression by Avastin served as control. To see
whether the MSC-secreted VEGF is able to contribute to
angiogenesis, we added MSC supernatant to HUVEC. This resulted
in strong induction of sprouting in similar intensity as observed
with the addition of recombinant VEGF alone (Figure 3C). Owing
to this obvious angiogenic potential of MSC, we examined the
differentiation of MSC into endothelial cells by culturing the MSC
for 1, 2, or 3 weeks in endothelial cell culture medium containing
VEGF. However, even after prolonged time, we could detect the
expression of typical endothelial cell markers, such as CD31 or von
Willebrand factor only in very few (about 0.01%) MSC (Figure 3D).
In contrast, HUVECs, which were used as positive control, strongly
expressed these typical markers for endothelial cells. However,
10% of MSC from the same fraction kept their differentiation
potential to osteocytes and adipocytes as tested by culture in
specific differentiation media as described (data not shown).
Therefore, the differentiation of MSC into endothelial cells may be
neglected as a main factor responsible for an angiogenic potential
of MSC.
Spheroids MSC
Spheroids MSC Overlay
0 h
1 h
2 h
3 h
4 h
5 h
6 h
PC
Figure 2 Migration of MSC to spheroids of pancreatic tumour cells.
(A) Green-labeled spheroids (composed of 5 10
2 MIA-PaCa-2,
2.5 10
2 human primary fibroblasts, and 2.5 10
2 HUVEC) and red-
labeled MSC were seeded in opposite edges of a well of a 24-well plate
and covered with methocel/collagen solution as described in Materials and
methods. (B) Cells were analysed using a fluorescence microscope
(Olympus IX 70) with a red and green filter, 20-fold magnification and two-
fold binning immediately after seeding. The focus was put to spheroids.
Migration of red fluorescent MSC to green fluorescent spheroids was
monitored by time-lapse photography during a period of 12h and a picture
was taken every 5min. Representative data of one experiment out of three
similar is shown.
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sMigration of MSC in tumour blood vessels and attachment
to vessel endothelium
Mice with human orthotopic pancreatic cancer xenografts were
injected with LV-transduced MSC (4 10
5 in tail vein) conferring
the expression of enhanced green fluorescent protein (eGFP).
Xenografted mice, which did not receive MSC, served as controls.
Three days later, mice were killed followed by resection of
xenografts and organs. Isolated cells were examined by flow
cytometry for eGFP expression (Figure 4A). The highest eGFP
expression was observed in tumour xenografts, but a minor
percentage was also detected in normal organs, such as the lung,
spleen, and kidney but not in the liver or heart. Weak green
fluorescence was observed in tumours of mice that did not receive
MSC, suggesting autofluorescence of the mouse tissue. This result
indicates a tumour-specific migration of MSC and demonstrates
that few MSC reside in other organs according to a natural
function of MSC in tissue remodelling (Jiang et al, 2002). To see
whether MSC influence tumour angiogenesis, we injected MSC
with lentiviral control vector or with lentiviral siRNA into mice
with orthotopic MIA-PaCa-2 xenografts. Three days later, cryosec-
tions of xenografts were examined for the expression of CD31 to
detect blood vessels. To quantify the density of blood vessels, we
counted CD31
þ structures per high-power field ( 250) (Figure
4B and C). By this way, we found that MSC with empty vector lead
to a doubling of blood vessels in contrast to mice that received no
MSC or MSC with siRNA-inhibited VEGF expression. As siVEGF
lead to a strong inhibition of VEGF protein secretion in transduced
MSC (Figure 4D), the production of VEGF by MSC may be a major
reason for the angiogenic capacity of MSC.
Intravital microscopy of MSC recruitment in mice
To further elucidate the process of MSC homing in vivo,w e
monitored microcirculation in cremaster muscle and in orthotopic
Mia-PaCa-2 xenograft tumours using fluorescence intravital
microscopy immediately after intraarterial injection of MSC
expressing eGFP. Within 5–10s after the injection of MSC, the
green fluorescent cells appeared in the inflamed cremasteric
microcirculation, first freely flowing in small arteries and
arterioles, and later in the capillary network where some of them
got already stuck. As soon as 1min after MSC administration,
eGFP
þ cells were detectable in the cremasteric venular tree
(Figure 5A, Supplementary Figure S1). We observed firm arrest of
individual MSC in cremasteric venules and veins (vessel diameter
120mm, centerline blood flow velocity of 2100mms
 1 with a
resulting wall shear rate of 700s
 1). Although technically more
challenging, we were able to observe MSC homing in the xenograft
tumours similar to MSC recruitment in cremaster muscle. After
arterial circulation, some MSC adhered in tumour capillaries and
later also in tumour venules and veins (vessel diameter 45mm,
centerline blood flow velocity of 800mm/s with a resulting wall
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Figure 3 Mesenchymal stem cells induce sprouting of endothelial cells by VEGF expression but do not differentiate into endothelial cells. (A) Vascular
endothelial growth factor protein in supernatant of MSC cultured under hypoxic (black bars) or normoxic (white bars) conditions in the presence or
absence of Avastin (25mgml
 1) was analysed by the ELISA assay. (B) RNA expression of VEGF was analysed by RT-PCR in MSC. The expression of a-SMA
served as control for equal conditions. (C) A volume of 100 or 200ml supernatant from MSC (as indicated), which have been cultured in medium containing
2% FCS for 48h or recombinant VEGF (50ngml
 1), was transferred to spheroids consisting of 1 10
3 HUVEC growing in wells of a 24-well plate 48
spheroids per well. The length of sprouts was analysed by cell
B 2.3 software and median lengths are given. Representative spheroids have
been visualised by phase-contrast microscopy using an Olympus CKX41 microscope,  10 magnification, and a colorview camera soft imaging system.
(D) Mesenchymal stem cells were seeded on chamber slights covered with fibronectin and cultured in endothelial cell medium containing VEGF (50ngml
 1)f o r
2 weeks. Immunohistochemistry was performed using specific antibodies for the detection of the specific endothelial cell markers von-Willebrand factor (a-vWF)
and CD31 (a-CD31). Human umbilical vein endothelial cells were used as positive control. A Leica DMRB microscope and  1000 magnification were used.
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sshear rate of 700s
 1) (Figure 5B, Supplementary Figure S2). A few
of the observed MSC detached 30s after initial arrest. The
attachment of MSC to vascular endothelium was confirmed by
immunofluorescence staining of an eGFP-expressing MSC within
vWF-positive endothelial cells within a tumour vessel of a
pancreatic cancer xenograft (Figure 5C).
DISCUSSION
Cellular therapy with human MSC has great potential for use in
regenerative medicine and is currently in clinical development.
Mesenchymal stem cells are being investigated in the treatment of
bone and cartilage defects, and injured myocardium after acute
infarction (Giordano et al, 2007). The ability of MSC to
differentiate into several lineages of connective tissue is well
documented (Prockop, 1997). Recent evidence has suggested that
MSC may also differentiate into endothelial and vascular smooth
muscle cells (Oswald et al, 2004). In this report, we set out to
clarify molecular mechanisms of MSC migration towards tumour
blood vessels and the cellular fate of implanted MSC in
participating in vasculogenesis in vivo. Our study shows the
migration of MSC towards growth factors secreted by growing
tumour and normal cells, with PDGF as most potent chemoat-
tractant, followed by EGF and VEGF, in line with recent findings
(Nakamizo et al, 2005; Schmidt et al, 2006a). Moreover, we found
the secretion of VEGF by MSC itself under basal conditions and the
enhancement of VEGF mRNA and protein secretion into the
supernatant by hypoxia. As expected, the transfer of supernatant
from MSC to HUVEC increased sprouting, supporting the
angiogenic potential of MSC. Therefore, VEGF production by
MSC may be a crucial factor responsible for an angiogenic
potential of MSC. Another reason for contribution of MSC to
angiogenesis may be the differentiation of MSC in endothelial cells
as recently suggested (Oswald et al, 2004; Silva et al, 2005; Song
et al, 2007). As these data are unclear, we tried to differentiate MSC
into endothelial cells by culturing them in endothelial cell culture
medium with VEGF. However, we found the differentiation of only
few MSC below 0.01% into cells expressing vWF, a typical marker
of vascular endothelial cells. The majority of MSC remained
undifferentiated under these conditions, although the differentia-
tion potential into adipocytes and osteocytes was intact in the
same fractions. The reason for this low differentiation capacity into
endothelial cells may be of experimental nature due to suboptimal
growth conditions for MSC in endothelial cell culture medium.
After 3 weeks in this medium, the MSC resembled rather senescent
cells than endothelial cells. However, the differentiation capacity of
MSC into endothelial cells is underlined by other reports. In 1999,
Barry et al (1999) identified the endothelial marker endoglin
(CD105) in BM-derived MSC grown on an endothelial cell-specific
membrane. Although undifferentiated BM-derived MSC did not
express vWF (Hu et al, 2003), expression of this and some
molecules specific to endothelial cells was found after endothelial
differentiation on the cell surface of MSC (Oswald et al, 2004; Sun
et al, 2005). But blood vessels are not only composed of endothelial
cells. Endothelial cells constitute the inner lining of the vessel wall,
and pericytes and vascular smooth muscle cells (summarised as
mural cells) envelop the surface of the vascular tube in mature,
stable vessels. During the early stage of angiogenesis, neovascular
sprouts are composed primarily of endothelial cells and are
subsequently stabilised by recruiting mural cells (Jain, 2003).
Human MSC implanted in immunodeficient mice recruit into
blood vessels as shown by our immunohistochemistry and
microcirculation studies. However, we did not detect in vivo
differentiation of MSC into endothelial cells and the function of
MSC in endothelium is unclear so far. In related models, it has
been described that co-implantation of HUVEC with a murine
mesenchymal precursor cell line (10T1/2) that differentiates into
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Figure 4 Migration of MSC in orthotopic MIA-PaCa-2 pancreatic
xenografts in nude mice and the incorporation in tumour blood vessels.
(A) Four mice with MIA-PaCa-2 orthotopic pancreatic cancer xenografts
were injected with lentiviral eGFP-labeled MSC (4 10
5 in tail vein). Four
xenografted mice received PBS injection and served as controls. Three days
after injection, mice were killed followed by the resection of organs and
xenografts. Cells were isolated from tissue pieces and examined by flow
cytometry for expression of green fluorescence of eGFP-expressing MSC.
Mean bars±s.e. are shown. (B) Four xenografted mice per group were
injected with PBS only (no MSC) or with MSC transduced with lentiviral
control vector (VEC-CO), or with MSC transduced with lentiviral siRNA
towards VEGF (siVEGF). Three days later, microvessel density in
cryosections of xenografts was analysed by immunohistochemistry for
CD31 in a Leica DMRB microscope with 250-fold magnification.
Microvessel density was quantified using eight images from each of four
different tumours per group. Microvessels per field of 1mm
2 were counted.
(C) Data from one representative staining per group are shown. (D)
Vascular endothelial growth factor protein in supernatant of MSC
transduced with lentiviral control vector (VEC-CO) or with siRNA towards
VEGF (siVEGF) cultured under normoxic (white bars) or hypoxic (black
bars) conditions was analysed by the ELISA assay. Statistical significance was
determined by t-test (Po0.05) and is indicated by an asterisk.
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smural cells is necessary for the formation of long-lasting blood
vessels (Koike et al, 2004). In consequence, MSC may be a source
for mural cells or be involved in recruitment of them. A recent
publication points to this direction, as co-implantation of HUVEC
and human MSC in immunodeficient mice was able to form human
mature blood vessels, which are stable and functional for more than
3 months (Sanz et al, 2008). Another recent study suggested MSC as
perivascular cell precursors and MSC seem to contribute to a
functional vasculature by differentiation into pericytes (Au et al,
2008). In vivo, we detected homing of MSC to tumour blood vessels
of an orthotopic pancreatic carcinoma xenograft in immunodefi-
cient mice. After injection of MSC in tail vein, we found enhanced
vessel density by control MSC but not by MSC expressing siRNA
directed towards VEGF. Therefore, our data suggest that VEGF
production by MSC is the critical factor mediating the angiogenic
potential of MSC. Tumour hypoxia, a feature typical for pancreatic
cancer may further increase the angiogenic effect of MSC, as our
in vitro data show the expression of HIF-1a by pancreatic cancer
cells under hypoxic conditions, which, in turn, leads to expression
and secretion of VEGF by tumour cells. Enhanced VEGF levels may
increase migration of MSC, which, after recruitment to pancreatic
tumours, itself produce VEGF and contribute by this way to the
hypoxia-initiated angiogenic effect.
For in vivo detection of MSC recruitment in trauma-induced
inflammation of cremaster muscle and orthotopic MIA-PaCa-2
xenograft tumours, we used intravital microscopy. By this way, we
found a very early arterial circulation of injected MSC followed by
a final arrest of some MSC in the capillary network, which is likely
to be due to obstruction. Other MSC were detected in the venular
tree as early as 1min after MSC administration where some of
them adhered firmly to the endothelium. Only very few transiently
attached MSC detached again from the vessel wall. Although there
are some rolling MSC detectable, the rather sudden arrest of MSC
seems to be similar to the VCAM-1-dependent fashion of leukocyte
adhesion triggered by VLA-4 (Ley et al, 2007). As VLA-4 is known
to be expressed on MSC and VCAM-1 on inflamed vascular
endothelium (Ley et al, 2007), one may hypothesise an in vivo
relevance of the interaction of these two molecules during MSC
recruitment as supported by recent studies (Ruster et al, 2006;
Segers et al, 2006). Furthermore, similar to leukocytes, MSC seem
to be recruited preferentially in low flow (capillaries) or medium
flow (venules) vessels providing optimal haemodynamic condi-
tions, that is, wall shear rate (Long et al, 2004). With these respects
to leukocyte recruitment, further elucidation of exact mechanisms
of the early steps of MSC recruitment into both peripheral tissue
and neoplasic tumours is required.
In conclusion, we demonstrate that human MSC from BM
specifically migrate to tumour blood vessels of pancreatic carcinoma
in vitro and in vivo, which can be attributed to tumour hypoxia-
induced secretion of VEGF and other growth factors. We observed
long-term (3 days) interaction of MSC with the endothelium of
tumour blood vessels. Very few of MSC differentiated into
endothelial cells in vitro, whereas no differentiation in vivo could
be observed. We found high VEGF production by MSC, which was
further enhanced by hypoxia. Therefore, secretion of VEGF may be
the crucial factor determining the angiogenic potential of MSC.
However, before these findings can be used for the creation of
optimised treatment schedules in patients, one should keep in mind
that the role of MSC is complex and these stem cells interact with
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Figure 5 Recruitment of MSC in mice by intravital microscopy reveals
attachment to normal and tumour blood vessels. Mice with MIA-PaCa-2
orthotopic pancreatic cancer xenografts were injected with lentiviral GFP-
transduced MSC (four consecutive injections of 10
5 MSC per 0.2ml normal
saline in time intervals of about 15min) into the carotid artery. Photographs
of circulating MSC in (A) cremaster muscle and (B) tumour vessels were
taken and analysed as described in Materials and methods. Circulating
(white arrow) and attached (white asterisk) green fluorescent MSC
appeared during the first minute after injection. Red arrows indicate the
direction of flow. a, artery; v, venule. Pictures are freezed images from video
sequences provided in the supplement. (C) Immunofluorescence staining
of a GFP-expressing MSC incorporated in vWF-positive endothelial cells of
a vessels was detected in an orthotopic pancreatic xenograft of nude mice,
which have been injected with MSC as described in Figure 4.
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smultiple other molecules and cells. The results of our study are
limited by the use of only one pancreatic cancer cell line. But cancer
cells differ and further experiments are necessary to fully under-
stand the complex function of MSC in the organism.
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